DCPH - Deciphera's Qinlock granted marketing authorization in U.K. for gastrointestinal stromal tumor

Deciphera Pharmaceuticals (NASDAQ:DCPH) perks up 3.7% premarket following an announcement that the U.K.'s Medicines and Healthcare products Regulatory Agency has granted marketing authorization for Qinlock (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST). The approval was supported by efficacy results from the primary analysis of Phase 3 INVICTUS study in patients with advanced GIST as well as combined safety results from INVICTUS and the Phase 1 study of QINLOCK. Qinlock is a switch-control tyrosine kinase inhibitor that was engineered to broadly inhibit KIT and PDGFRA mutated kinases by using a dual mechanism of action that regulates the kinase switch pocket and activation loop.

For further details see:

Deciphera's Qinlock granted marketing authorization in U.K. for gastrointestinal stromal tumor